Vasopressin-receptor antagonists. - Wikidata - awgldk - TriplyDB

Vasopressin-receptor antagonists.

Vasopressin-receptor antagonists.

http://www.wikidata.org/entity/Q37770574

about

Tolvaptan.Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines.Effects of dietary cadmium exposure on osmoregulation and urine concentration mechanisms of the semi-desert rodent Meriones shawi.

P2860

Q34052281-45333CE9-CDD8-47DB-94D3-655E2D34A73C Q39125114-1A2CF382-2554-4F6B-BFDB-3E0BBA7D6299 Q39229891-F094BA88-913C-41E8-AB3A-D3ACAB644D69

P2860

Vasopressin-receptor antagonists.

http://www.wikidata.org/entity/Q37770574

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Vasopressin-receptor antagonists.

@en

Vasopressin-receptor antagonists.

@nl

type

label

Vasopressin-receptor antagonists.

@en

Vasopressin-receptor antagonists.

@nl

prefLabel

Vasopressin-receptor antagonists.

@en

Vasopressin-receptor antagonists.

@nl

P1433

Q37770574-48F320D4-7DFB-474B-A9E1-060BA3CBFBC6

P1476

Q37770574-9721BE5D-FFDA-4B52-8F20-7D14F5FBF3AD

P2093

Q37770574-27C2F17E-0EF2-4112-86E4-8082669C369F

Q37770574-DB272CD3-6DAB-49E2-B096-034266876D2B

P2860

Q37770574-03776702-4039-4B77-8AC4-5D176BCC9359

Q37770574-0420C23F-96A9-453A-8821-743D0DB77874

Q37770574-065593DC-B393-4011-BF7D-6F1D5CAB2045

Q37770574-16A1A2CD-3145-4898-B7B5-53E8A4F5BB94

Q37770574-1997F7E7-FD4E-4DE3-9E84-2E202CB5D7E9

Q37770574-242374A9-F87C-4928-98A6-0CA69B5C87BF

Q37770574-297D1341-154C-4600-B52C-B943A1AF8FF9

Q37770574-348FF551-F8E1-4B75-84F5-4A7BCD3DCC77

Q37770574-34B00F68-3322-4998-A55F-FCEAB5F18F0A

Q37770574-35417B1E-B5AE-4277-A716-22121093CED9

P304

Q37770574-F5F71279-E5F2-4505-B260-B7094790854B

P31

Q37770574-BC01E397-D0A4-4511-8A3A-E43B0E08BB3E

P356

Q37770574-4E639B95-40EF-4AA8-AFF4-1D98288DA944

P433

Q37770574-1FFDC069-B791-4EFA-B07C-C91A3E7750E1

P478

Q37770574-13BE4BFF-1565-4A99-98E2-CB38D1925CB1

P577

Q37770574-D78BF46A-A2CC-4F8A-9C50-1B83EA4BB780

P698

Q37770574-3A62B4F1-A5E8-4B52-B03D-C05F2FD8D814

P921

Q37770574-9245ead0-4fe3-44c8-841a-85b03e1fffa8

P356

P1433

Future Cardiology

P1476

Vasopressin-receptor antagonists.

@en

P2093

Ewout J Hoorn

http://www.w3.org/2001/XMLSchema#string

Robert Zietse

http://www.w3.org/2001/XMLSchema#string

P2860

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

Vasopressin receptor antagonists

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents

Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists

Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

Copeptin in the differential diagnosis of hyponatremia.

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

Aquaporins in the kidney: from molecules to medicine.

P304

523-534

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FCA.10.22

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20608824

http://www.w3.org/2001/XMLSchema#string

P921